口服减重药获批之后：处方从医院流向哪里，谁来决定“每天一片”的可及性

同花顺11-13 16:28

国内首个口服GLP-1减重药落地了。国家药监局官网显示，礼来（LLY）申报的奥氟格列隆钙片（商品名穆优达）获批上市，适应症写得克制：在控制饮食和增加运动基础上，用于肥胖或超重并伴有至少一种体重相关合并症的成人体重管理。不是所有超重人群，更不是普通意义上的“想瘦几斤”。这条适应症边界，是理解后续一切商业节奏的起点。同一时间窗口里，礼来（LLY）宣布未来十年累计投资30亿美元扩展在华供应链，重点打造...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2683578406?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-11-13 16:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2683578406","market":"sh","top_or_hot":-1,"title":"口服减重药获批之后：处方从医院流向哪里，谁来决定“每天一片”的可及性","media":"同花顺","content":"<div>\n<p>国内首个口服GLP-1减重药落地了。国家药监局官网显示，礼来（LLY）申报的奥氟格列隆钙片（商品名穆优达）获批上市，适应症写得克制：在控制饮食和增加运动基础上，用于肥胖或超重并伴有至少一种体重相关合并症的成人体重管理。不是所有超重人群，更不是普通意义上的“想瘦几斤”。这条适应症边界，是理解后续一切商业节奏的起点。同一时间窗口里，礼来（LLY）宣布未来十年累计投资30亿美元扩展在华供应链，重点打造...</p>\n\n<a href=\"http://news.10jqka.com.cn/20261113/c681803265.shtml\">网页链接</a>\n\n</div>\n","source":"tonghuashun_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>口服减重药获批之后：处方从医院流向哪里，谁来决定“每天一片”的可及性</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n口服减重药获批之后：处方从医院流向哪里，谁来决定“每天一片”的可及性\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-13 16:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://news.10jqka.com.cn/20261113/c681803265.shtml><strong>同花顺</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>国内首个口服GLP-1减重药落地了。国家药监局官网显示，礼来（LLY）申报的奥氟格列隆钙片（商品名穆优达）获批上市，适应症写得克制：在控制饮食和增加运动基础上，用于肥胖或超重并伴有至少一种体重相关合并症的成人体重管理。不是所有超重人群，更不是普通意义上的“想瘦几斤”。这条适应症边界，是理解后续一切商业节奏的起点。同一时间窗口里，礼来（LLY）宣布未来十年累计投资30亿美元扩展在华供应链，重点打造...</p>\n\n<a href=\"http://news.10jqka.com.cn/20261113/c681803265.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0174119429.USD","symbol_name":"T ROWE PRICE US LARGE CAP GROWTH EQUITY \"A\" ACC","start_time":0,"source_url":"http://news.10jqka.com.cn/20261113/c681803265.shtml","article_id":"2683578406","we_media_id":null,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261113/c681803265.shtml","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2683578406","pubTimestamp":1794558480,"columns":[],"sourceInfo":{"source_id":"tonghuashun_highlight","name":"同花顺"},"weMediaInfo":null,"summary":"国内首个口服GLP-1减重药落地了。国家药监局官网显示，礼来申报的奥氟格列隆钙片（商品名穆优达）获批上市，适应症写得克制：在控制饮食和增加运动基础上，用于肥胖或超重并伴有至少一种体 ...","collect":0,"end_time":0,"defaultTopTitle":"10jqka.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0174119429.USD":"T ROWE PRICE US LARGE CAP GROWTH EQUITY \"A\" ACC","LU2063271972.USD":"富兰克林创新领域基金","LU0058720904.USD":"联博国际健康护理基金A","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2462591350.SGD":"T ROWE PRICE US LARGE CAP GROWTH EQUITY \"AN\" (SGDHDG) ACC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","TMED":"T. Rowe Price Health Care ETF","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2211817866.USD":"Allianz Food Security AT Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","RXL":"ProShares Ultra Health Care","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0238689110.USD":"贝莱德环球动力股票基金","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1979441026.SGD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"A\" (SGDHDG) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","BK4588":"碎股","CURE":"Direxion Daily Healthcare Bull 3X ETF","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","CANC":"TEMA ONCOLOGY ETF","LLYX":"2倍做多LLY ETF-Defiance","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","ELIL":"2倍做多LLY ETF-Direxion","BK4599":"减肥药","LLYZ":"2倍做空LLY ETF-Defiance","WDNA":"WisdomTree BioRevolution Fund","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","ELIS":"1倍做空LLY ETF-Direxion","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0385154629.USD":"贝莱德营养科学基金A2","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","PPH":"VanEck Pharmaceutical ETF","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IYH":"iShares U.S. Healthcare ETF","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","GDOC":"Goldman Sachs Future Health Care Equity ETF","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","OZEM":"Roundhill GLP-1 & Weight Loss ETF","XLV":"健康照护类股ETF-SPDR","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","HRTS":"Tema Heart & Health ETF","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LLY":"礼来","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LLII":"REX LLY Growth & Income ETF","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","BK4007":"制药","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","AGNG":"Global X Aging Population ETF","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","IHE":"iShares U.S. Pharmaceuticals ETF","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","IXJ":"全球医疗业ETF-iShares","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","VHT":"Vanguard Health Care ETF","BK4581":"高盛持仓","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","ILDR":"First Trust Innovation Leaders ETF","FHLC":"Fidelity MSCI Health Care Index","BK4534":"瑞士信贷持仓","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","MEDI":"HARBOR HEALTH CARE ETF","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","MEDX":"HORIZON KINETICS MEDICAL ETF","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","BK4516":"特朗普概念","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","PJP":"INVESCO PHARMACEUTICALS ETF","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","MHIP":"Milliman Healthcare Inflation Plus ETF","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","TRUH":"VanEck Healthcare TruSector ETF","LU0882574139.USD":"富达环球消费行业基金A ACC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","SG9999015978.USD":"利安颠覆性创新基金A","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0133085943.USD":"T ROWE PRICE US BLUE CHIP EQUITY \"A\" ACC","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC"},"translate_title":"After the approval of oral weight loss drugs: where does the prescription flow from the hospital, who will decide the accessibility of \"one pill a day\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXL":0.6,"LLYZ":0.6,"THNR":0.6,"VHT":0.6,"JDOC":0.6,"CURE":0.6,"LLY":1.97,"PJP":0.6,"CANC":0.6,"HRTS":0.6,"LLYX":0.6,"MEDX":0.6,"MEDI":0.6,"MHIP":0.6,"AGNG":0.6,"OZEM":0.6,"ELIS":0.6,"FTXH":0.6,"IXJ":0.6,"TRUH":0.6,"LLII":0.6,"PPH":0.6,"XLV":0.6,"WDNA":0.6,"GDOC":0.6,"IYH":0.6,"ELIL":0.6,"TMED":0.6,"ILDR":0.6,"IHE":0.6,"FHLC":0.6},"content_text":"国内首个口服GLP-1减重药落地了。国家药监局官网显示，礼来（LLY）申报的奥氟格列隆钙片（商品名穆优达）获批上市，适应症写得克制：在控制饮食和增加运动基础上，用于肥胖或超重并伴有至少一种体重相关合并症的成人体重管理。不是所有超重人群，更不是普通意义上的“想瘦几斤”。这条适应症边界，是理解后续一切商业节奏的起点。同一时间窗口里，礼来（LLY）宣布未来十年累计投资30亿美元扩展在华供应链，重点打造口服固体制剂本土生产与供应体系。获批与产能前置几乎同步发生，市场很容易把这两件事读成“放量在即”。但药品从获批到患者手里，中间是一条由药事委员会、处方习惯、支付能力和随访管理共同构成的窄路。每条路上都有决策主体，每个主体都有自己的摩擦系数。先看一个被反复引用的结构：IQVIA发布的《2026中国减重药物市场全景洞察报告》显示，GLP-1在院内渠道保持近100%的绝对主导地位。这意味着，即便口服剂型把“不用打针”的心理门槛拆掉了，患者第一次接触药物的场景，大概率仍然发生在医院（884301）诊室里。零售药房和线上平台在减重药上的承接角色，公开信息尚不足以给出规模判断。这构成第一层过滤。医生开不开，取决于两件事：处方习惯和药事准入。减重适应症的处方权并不只属于内分泌科，营养科、心血管科甚至全科都可能接触到目标患者，但奥氟格列隆的临床数据集中在肥胖症人群的ATTAIN-1研究里——最高剂量组治疗72周平均减重12.4%，约四成受试者减重至少15%，内脏脂肪平均减少超过30%。医生要消化这套数据，需要时间；而新品进院要过药事委员会，品规数量有上限，进院周期（883436）以季度计。获批当天的兴奋，和处方单上的第一笔，中间隔着好几个月。第二层过滤是支付。减重药目前自费属性强，口服剂型定价尚未披露，支付端承接方案也不明确。这里有一个容易被忽略的机制：便利性降低的是心理门槛，但自费掏钱降低不了价格敏感度。一个对针头恐惧的患者，可能因为“每天一片”走进诊室；但当他看到自费账单时，决定他是否持续用药的，是每月支出占可支配收入的比例，而不是剂型本身。便利性扩大了初诊人群，支付能力决定了转化率的天花板。两层叠加，才是真实渗透率。第三层过滤在处方流转。院内渠道主导意味着，药品从医院（884301）药房到患者手中的路径相对单一。处方流转平台能不能接入、零售渠道能不能承接长期处方、随访管理由谁来做，这些环节在减重药领域都还处在早期。诺和诺德（NVO）的渠道已从一二线城市三甲医院（884301）与连锁大药房向更广范围延伸，这个动作本身说明，单靠院内一条腿走路，覆盖半径有限。口服剂型要打开增量，需要院外承接能力跟上，而这块能力目前公开信息不足以确认规模。把三层过滤串起来，传导链就清楚了：口服便利性降低心理门槛，初诊人群扩大；但医生处方习惯和药事准入决定“开不开”，支付能力决定“用不用得起、用不用得久”，处方流转决定“拿不拿得到”。任一环节滞后，获批到放量的传导就会打折。最强反方在这里值得认真摆出来。对方的论据有分量：口服剂型直击针头恐惧、冷链储存、外出携带不便三大痛点，诺和盈片剂在美国上市后累计处方量超过800万张，其中超过八成使用者是此前未用过GLP-1的新人群——这证明便利性确实能撬动增量。奥氟格列隆每日一次、全天任意时间服用、不受饮食饮水限制，依从性优势更彻底。如果这套逻辑成立，口服剂型应该快速放量。我不同意的地方在于时间尺度和前提条件。美国市场的处方转化，建立在商业保险覆盖和成熟的处方流转体系上；国内减重药自费为主，院内主导，两者不能直接类比。更关键的是竞争节奏：诺和盈片剂用于长期体重管理的上市申请已于2026年8月获国家药监局受理，仍在评审中；奥氟格列隆抢到了“首个”标签，但先发窗口有多宽，取决于诺和盈片剂评审进度和礼来（LLY）进院速度的赛跑。如果诺和盈片剂在礼来（LLY）完成医院（884301）准入之前获批，先发优势会被压缩。市场预期和产业节奏的差异，恰恰在这里。市场交易的是“首个口服”这个标签，产业实际节奏取决于进院、支付、流转三条链路的同步程度。礼来（LLY）中国区前三季度收入25.82亿美元，同比增幅75%，显著高于美国36%、欧洲44%、日本25%的增速——这个数字说明中国市场的战略权重在上升，但不等于单品放量速度。战略权重是投入意愿，放量速度是渠道能力，两件事不能混为一谈。还有一个风险维度不能略过。2026年11月9日，FDA发布药品安全通告，要求所有GLP-1受体激动剂类药物在说明书“警告和注意事项”部分增加NAION（非动脉炎性前部缺血性视神经病变）风险提示；EMA此前已认定该风险为司美格鲁肽的极罕见不良反应。FDA同时明确，目前为潜在风险关联，尚未确立因果关系。诺和诺德（NVO）中国方面表示，司美格鲁肽国内说明书早在今年6月就已纳入NAION相关内容，但此前放在不良反应章节，未进入高优先级警告栏。这类安全性信号的监管层级变化，会影响医生处方时的风险沟通成本，尤其在新品教育阶段。它不会阻断放量，但会改变医生对“每天一片”的推荐语气。后续观察变量可以列得具体一些：奥氟格列隆在重点医院（884301）的药事准入进度，尤其是内分泌科之外科室的覆盖；处方流转平台是否接入减重药长期处方；支付端是否出现补充商业保险或药企患者支持方案；诺和盈片剂评审状态变化；以及礼来（LLY）30亿美元供应链投资中口服固体制剂产线的落地时间表。这些变量比“获批”本身更能指示放量节奏。结论的边界要交代清楚。在自费为主、院内主导、处方流转尚未规模化的前提下，口服剂型的便利性优势会在初诊人群扩大上先体现，但处方转化率受支付能力和渠道承接制约，获批到放量的传导会有明显时滞。若支付端出现补充方案、或处方流转平台在减重药上形成规模承接，上述判断需要修正。时间尺度上，进院周期（883436）以季度计，支付方案落地更慢，用月度数据去验证年度逻辑，容易误读。“每天一片”能不能变成每天有人用，答案不在获批公告里，在药事委员会的议程上、在患者的自费账单上、在处方流转平台的接入清单里。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2683578406","isCrawlerRequest":true}